---

Pneumonia - A Comprehensive Overview

---

Definition

• Textbook of Family Medicine 9e, p. 321
• Medical Microbiology 9e, p. 235

---

Classification

By Clinical Setting

By Pathogen Type

• Typical bacterial (e.g., Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus)
• Atypical (e.g., Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella pneumophila)
• Viral (influenza A/B, RSV, SARS-CoV-2, CMV)
• Fungal (Pneumocystis jirovecii, Cryptococcus, Coccidioides)

By Anatomic Pattern

• Lobar pneumonia - consolidation of an entire lobe (classic in pneumococcal)
• Bronchopneumonia - patchy infiltrates around bronchi (common in children, elderly)
• Interstitial pneumonia - involvement of alveolar walls/interstitium (typical of viral and atypical organisms)

---

Epidemiology

• Pneumonia/influenza is the primary diagnosis in over 1 million hospital admissions per year in the United States
• In-hospital death rate: ~3.3%
• Aggregate national hospital charges exceed $35 billion per year
• Globally, it remains a leading cause of death, especially in low- and middle-income countries and in children
• Children, elderly, and immunocompromised individuals are especially vulnerable
• Textbook of Family Medicine 9e, p. 321

---

Etiology & Common Pathogens

Community-Acquired Pneumonia (CAP)

• Streptococcus pneumoniae - the most common cause of bacterial CAP and lobar pneumonia; declining in children due to vaccination
• Haemophilus influenzae - common in COPD, elderly
• Mycoplasma pneumoniae - classic "atypical" or "walking pneumonia"
• Chlamydia pneumoniae, Legionella pneumophila - atypical pathogens
• Respiratory viruses - influenza, RSV, SARS-CoV-2

Hospital/Nursing Home Patients

• Gram-negative rods: Serratia, Pseudomonas, Klebsiella, E. coli
• Anaerobes (aspiration)
• Multidrug-resistant (MDR) bacteria

Immunocompromised Patients

• Pneumocystis jirovecii (PCP) - especially in HIV/AIDS
• Cryptococcus, Coccidioides immitis
• Atypical mycobacteria, CMV, fungi

Special Populations

• Alcoholics: H. influenzae, aspirated anaerobes (Peptostreptococcus, Bacteroides)
• Neonates: Group B Streptococcus, gram-negatives, Chlamydia trachomatis (6-8 weeks)
• Children: Viral pathogens predominate; S. pneumoniae most common bacterial cause; S. aureus causes aggressive pneumonia post-varicella/measles

---

Pathophysiology

Entry & Early Infection

1. Microaspiration of oropharyngeal secretions (most common)
2. Inhalation of aerosolized particles
3. Hematogenous seeding (rare)

Pneumococcal Pneumonia - Prototype

Hypoxemia Mechanism

• Shunt units (consolidated alveoli with no ventilation)
• Low V/Q regions

• Murray & Nadel's Textbook of Respiratory Medicine, p. 960

---

Clinical Presentation

Two Classic Patterns

• Abrupt onset, high fever (39-41°C) with shaking chills
• Productive cough - may have blood-tinged or rust-colored sputum
• Pleuritic chest pain
• Physical exam: decreased breath sounds, dullness to percussion, egophony on affected side
• WBC typically elevated (>15,000 x 10³/mm³) with neutrophil predominance

• Smoldering onset, low-grade fever
• Fewer constitutional symptoms
• Caused by Mycoplasma, Chlamydia, Legionella, or respiratory viruses
• Often called "walking pneumonia"

In Children

• Malaise, cough, chest pain, tachypnea (earliest clue - disproportionate to fever), intercostal retractions
• Viral: less toxic appearance, low-grade fever, wheezing
• Bacterial: appear acutely ill, high fever, chills, dyspnea

General Symptoms

---

Diagnosis

Chest X-Ray (CXR)

• Bacterial pneumonia: Lobar consolidation and alveolar infiltrates (radiographic changes lag 1-2 days behind clinical course; can be completely normal on day 1)
• Viral/atypical pneumonia: Patchy or streaky bilateral interstitial patterns + hyperinflation
• Parapneumonic pleural effusions may occur

Laboratory Tests

Severity Assessment Tools

• C - Confusion
• U - Urea >7 mmol/L
• R - Respiratory rate ≥30/min
• B - Blood pressure <90 systolic or ≤60 diastolic mmHg
• 65 - Age ≥65 years

---

Treatment

General Principles

• Treatment duration: minimum 5 days, and at least 48-72 hours beyond last fever/clinical instability
• Severity tools (PSI, CURB-65) should guide site-of-care decisions (outpatient vs. inpatient vs. ICU)

CAP - Outpatient (Mild, Healthy Adults)

• Amoxicillin OR
• Doxycycline OR
• Azithromycin/Clarithromycin (in areas with low macrolide resistance)

CAP - Inpatient (Non-ICU)

• Beta-lactam + macrolide (e.g., amoxicillin-clavulanate + azithromycin), OR
• Respiratory fluoroquinolone alone (levofloxacin, moxifloxacin)

CAP - ICU / Severe

• Beta-lactam + azithromycin or beta-lactam + respiratory fluoroquinolone
• Add MRSA coverage (vancomycin or linezolid) if MRSA risk factors present

HAP / VAP

• Broad-spectrum coverage targeting Gram-negatives and MRSA
• Agents: piperacillin-tazobactam, cefepime, or carbapenems ± vancomycin/linezolid

Atypical Organisms

• Mycoplasma/Chlamydia: macrolides or doxycycline
• Legionella: fluoroquinolones or azithromycin

Key Note

• Textbook of Family Medicine 9e, p. 322

---

Complications

Splenic Dysfunction

---

Prevention

Vaccines

• Influenza vaccine: Annually for patients >50 years, those with chronic lung disease, diabetes, immune dysfunction, or other chronic organ failure
• Pneumococcal vaccine (PCV/PPSV23):
  • Revaccinate after 10 years if the first vaccine was given before age 65
  • Universal pneumococcal vaccination in children has significantly reduced S. pneumoniae CAP

Infection Control

• Hand hygiene, isolation precautions
• Head-of-bed elevation at 30-45° for ventilated patients (shown to reduce VAP risk)
• Oral care bundles in ICU patients

---

Summary Table

---

• Textbook of Family Medicine 9e (Elsevier), pp. 321-323
• Medical Microbiology 9e, pp. 235-236
• Murray & Nadel's Textbook of Respiratory Medicine, p. 960
• IDSA/ATS Clinical Practice Guidelines for CAP (2019)

---

What This Covers (PGT Summary Map)

1. Acute Bronchitis/Tracheitis - definition, viral etiology, why antibiotics are NOT indicated, stewardship
2. CAP - full pathogens by setting, CURB-65, ATS/IDSA severe CAP criteria (with flowchart), antibiotic algorithm (outpatient → non-ICU → ICU → MRSA/Pseudomonas), 2026 ATS update
3. HAP/VAP - CDC/NHSN VAE surveillance algorithm (VAC → IVAC → possible/probable VAP), organism resistance profile, 7-day antibiotic target, PK/PD dosing principles
4. Aspiration Pneumonia and Lung Abscess - anaerobic microbiology, virulence factors, management
5. Empyema - pathophysiology and management
6. Diagnostics/Biomarkers - sputum quality, CRP-guided prescribing (NICE), procalcitonin, NGS

Key points to remember for exams:

• Acute bronchitis = no antibiotics (but 71% still get them - classic MCQ trap)
• CURB-65 score ≥3 = hospitalize; ATS major criteria (1 of 2) or minor criteria (3 of 9) = ICU
• HAP/VAP treatment = 7 days (not longer - more MDR with prolonged courses)
• Daptomycin is inactivated by pulmonary surfactant - cannot be used for lung infections
• Low procalcitonin does NOT rule out bacterial pneumonia - never withhold treatment on PCT alone

---

Asthma - Comprehensive PGT Guide (Respiratory Medicine)

---

1. Definition

Asthma is a disease characterized by episodic airway obstruction and airway hyperresponsiveness, usually accompanied by airway inflammation. In most cases, the obstruction is reversible, but in a subset of patients a component may become irreversible. In a large proportion, airway inflammation is eosinophilic, but some patients present with differing types (neutrophilic, mixed, or paucigranulocytic).

• Harrison's Principles of Internal Medicine 22E, Chapter 298

---

2. Epidemiology

• Affects ~300 million people worldwide; one of the most common chronic lung diseases
• Prevalence in adults: ~7-10% in high-income countries
• Increased prevalence with urbanization, Western lifestyle, obesity
• Can occur at any age; in children, more common in boys; in adults, more common in women
• Asthma deaths remain significant - GINA 2026 emphasizes fatality risk indicators as a new focus

---

3. Pathophysiology

3.1 Structural Changes in the Asthmatic Airway

3.2 Airway Inflammation - Type 2 vs Non-Type 2

Type 2 (T2) Inflammation (most common, ~50-70%)

• Driven by: ILC2s (innate lymphoid cells type 2), Th2 lymphocytes
• Key cytokines: IL-4, IL-5, IL-13 (+ alarmins TSLP, IL-25, IL-33 from epithelium)
• Hallmark: Eosinophilic inflammation
• Elevated FeNO (fractional exhaled nitric oxide), blood and sputum eosinophilia
• Responds to: ICS, anti-IL-5 (mepolizumab, reslizumab, benralizumab), anti-IL-4Rα (dupilumab), anti-IgE (omalizumab), anti-TSLP (tezepelumab)
• Eosinophil products (ECP, major basic protein) cause airway hyperresponsiveness, mucus hypersecretion, and peribronchiolar collagen deposition

Non-Type 2 (T2-Low) Inflammation

• Neutrophilic: Associated with more severe asthma, smoking, obesity, occupational exposures; often steroid-resistant
• Paucigranulocytic: No obvious airway inflammation - often smooth muscle predominant
• Mixed granulocytic: Both eosinophils and neutrophils - often the most severe phenotype

3.3 Mechanisms of Airway Hyperresponsiveness (AHR)

1. Structural: Airway wall thickening (smooth muscle hypertrophy + hyperplasia + subepithelial fibrosis) → disproportionate airway narrowing
2. Inflammatory: Activated mast cells, eosinophils, T-cells release bronchoconstrictors (histamine, leukotrienes, prostaglandins)
3. Neurogenic: Stimulation of sensory nerves → reflex bronchoconstriction
4. Epithelial disruption: Epithelium-mesenchyme trophic unit → releases growth factors contributing to remodeling
5. Lymphatics: Decreased lymphatic vessel density in fatal asthma → airway edema, fibrotic changes, despite elevated VEGF-C/D

3.4 Airway Smooth Muscle (Three Roles)

1. Hyperresponsive to stimuli
2. Hypertrophy + hyperplasia → airway wall thickening
3. Produces chemokines/cytokines → promotes airway inflammation and mast cell survival

3.5 Subepithelial Changes (Remodeling)

• Thickening of the subepithelial basement membrane from deposition of:
  • Repair-type collagens, tenascin, periostin, fibronectin, osteopontin
  • Primarily from myofibroblasts under the epithelium
• Stiffens the airway, narrows the lumen, impairs relaxation → chronic airway obstruction

3.6 ICS Pharmacology - Key PGT Points

• ICS are the mainstay of maintenance therapy
• Corticosteroids reduce type 2 inflammation and airway hyperresponsiveness
• Oral bioavailability comparison (critical to reduce systemic side effects):
  • Beclomethasone: ~20%
  • Fluticasone: ~1%
  • Mometasone: <1%
  • Ciclesonide: Not activated until it deposits in lung tissue (pro-drug)
• Up to 80% of pMDI/DPI dose deposits in oropharynx - hence importance of low oral bioavailability
• Systemic effects of ICS: short-term growth suppression in children, decreased bone mineral density, possible increased cataracts
• Asthmatic airways have more proximal deposition of ICS (due to reduced airway caliber) → less systemic absorption than normal subjects

---

4. Classification / Phenotypes

GINA Severity Classification (Based on treatment step)

• Mild: Controlled on Step 1-2 (low-dose ICS or ICS/formoterol as-needed)
• Moderate: Controlled on Step 3 (low-dose ICS/LABA)
• Severe: Requires Step 4-5 or remains uncontrolled despite Step 4-5

Phenotypes (Clinical)

---

5. Triggers

---

6. Clinical Features

Symptoms (Classic Triad)

• Episodic wheezing (expiratory > inspiratory)
• Shortness of breath (worse on exertion, at night, or after exposure to triggers)
• Chest tightness
• Cough (may be the only symptom - "cough-variant asthma")
• Symptoms often worse on arising in the morning or at night
• History of atopy (eczema, rhinitis, food allergies) is common

Physical Examination

• May be completely normal between attacks
• During attacks: expiratory wheeze, prolonged expiration, use of accessory muscles, hyperinflated chest
• Severe attack: silent chest (no wheeze due to minimal air entry - DANGER sign), cyanosis, pulsus paradoxus, inability to complete sentences

Asthma Control Assessment (GINA)

---

7. Diagnosis

Step 1: Compatible History

⚠️ Important: More than one-third of patients with a physician diagnosis of asthma do NOT meet diagnostic criteria. Always confirm with objective testing.

Step 2: Pulmonary Function Tests

• FEV₁/FVC ratio <0.70 (or below LLN) confirms obstruction
• Post-bronchodilator FEV₁ improvement ≥12% AND ≥200 mL = significant reversibility (confirms asthma)
• Post-BD FEV₁ improvement ≥10-15% from baseline = positive

• Variability >10% (am vs pm, or day-to-day) is suggestive
• Portable, inexpensive, useful for monitoring in moderate-severe asthma and pregnant women

• Methacholine or histamine challenge
• PC20 (provocative concentration causing 20% fall in FEV₁): <8 mg/mL = positive AHR
• ATS impairment rating uses PC20 alongside FEV₁ and medication need

• Marker of eosinophilic (T2) airway inflammation
• ≥40 ppb = elevated, suggests eosinophilic asthma, predicts ICS response
• <25 ppb = ICS-responsive eosinophilic inflammation less likely

Step 3: Adjunctive Evaluation

---

8. Comorbidities

---

9. Medications

9.1 Beta-2 Agonists

• Albuterol (salbutamol): onset 3-5 min, duration 4-6 h; MDI or nebulizer
• Indicated for reliever (rescue) therapy
• Regular use → tachyphylaxis of bronchoprotective effect; associated with increased mortality when used without ICS
• β₂-receptor polymorphism at amino acid 16 → increased airway reactivity with regular SABA use

• Salmeterol (slow onset), Formoterol (rapid onset, comparable to SABA)
• NEVER use as monotherapy in asthma (increased mortality risk)
• Always combine with ICS

• Indacaterol, olodaterol, vilanterol
• Only used in combination with ICS in asthma

9.2 Inhaled Corticosteroids (ICS)

• Beclomethasone (dipropionate) - older, 20% oral bioavailability
• Budesonide - moderate bioavailability, safe in pregnancy
• Fluticasone propionate - ~1% oral bioavailability
• Mometasone - <1% oral bioavailability
• Fluticasone furoate - ultra-LABA combination (vilanterol)
• Ciclesonide - pro-drug, activated only in lung tissue, minimal systemic effects

9.3 Anticholinergics (Muscarinic Antagonists)

• SAMA (ipratropium): Used for acute severe asthma (combined with SABA in emergency)
• LAMA (tiotropium): Add-on therapy at Step 4-5; can be used instead of LABA in some patients
• ICS/LAMA approved for asthma in adults; some concern of numerical (not significant) increased mortality in African Americans vs ICS/LABA

9.4 Leukotriene Receptor Antagonists (LTRAs)

• Montelukast, zafirlukast, pranlukast
• Alternative controller at Step 2; useful for aspirin-exacerbated disease and exercise-induced asthma
• ⚠️ FDA black box warning: Montelukast associated with serious neuropsychiatric effects including suicidal ideation - this limits use as first-line alternative

9.5 Theophylline

• Now rarely used due to narrow therapeutic window, drug-drug interactions, and reduced bronchodilation vs other agents
• Occasionally used as add-on in Step 4-5 in resource-limited settings

9.6 Anti-IgE Therapy

• Omalizumab (anti-IgE monoclonal antibody): for moderate-severe allergic asthma; eligibility - perennial allergen sensitization, elevated total IgE
• Reduces exacerbations, emergency visits, steroid use
• GINA 2026: also approved for CRSwNP (along with omalizumab-igec biosimilar)

9.7 Anti-IL-5 / Anti-IL-5Rα

• Mepolizumab (anti-IL-5): SC, every 4 weeks; blood eosinophils ≥150-300/µL
• Reslizumab (anti-IL-5): IV, weight-based; blood eosinophils ≥400/µL
• Benralizumab (anti-IL-5Rα): SC, every 4 weeks (then every 8 weeks); produces near-complete eosinophil depletion; blood eosinophils ≥300/µL
• Depemokimab (NEW - GINA 2026): approved for severe eosinophilic asthma ≥12 years; also approved for CRSwNP ≥18 years; long-acting biologic

9.8 Anti-IL-4Rα

• Dupilumab: Blocks both IL-4 and IL-13 signaling; for moderate-severe eosinophilic/type 2 asthma; also effective for CRSwNP and atopic dermatitis (addresses "one airway, one disease")

9.9 Anti-TSLP

• Tezepelumab: Anti-TSLP (targets most upstream alarmin); effective even in patients without classic T2 biomarkers; broad efficacy across phenotypes including non-eosinophilic asthma; GINA 2026 includes it in CRSwNP indication

---

10. Stepwise Management (GINA 2026 / NAEPP Framework)

Key Paradigm Shift - Anti-Inflammatory Reliever (AIR)

A landmark change: ICS/formoterol (single inhaler) used as-needed for relief - instead of SABA alone - is now the preferred approach at all steps. This reduces severe exacerbations and OCS use by ensuring anti-inflammatory therapy accompanies every bronchodilator dose.

• Based on: Type 2 biomarkers (FeNO, blood eosinophils, IgE), comorbidities (AERD, CRSwNP, atopic dermatitis), cost, dosing frequency, route of administration, patient preference
• All biologics in GINA 2026 decision tree are for T2 inflammation

• Step UP after 2-3 months of poor control (rule out: poor adherence, poor technique, ongoing exposure, comorbidities first)
• Step DOWN when well-controlled for ≥3 months (avoid discontinuing ICS entirely)

• All patients must receive ICS-containing therapy
• ICS/formoterol or ICS/SABA as AIR reduces the risk of severe exacerbations requiring OCS
• Treat modifiable risk factors; improve inhaler technique; patient education

---

11. Acute Severe Asthma (Asthma Attack)

Assessment of Severity

⚠️ A normal or rising PaCO₂ in a severe asthma attack indicates fatigue and impending respiratory failure - prepare for intubation.

GINA 2026 - Acute Management

• SABA (salbutamol 4-8 puffs via MDI with spacer OR nebulizer) up to every 1h
• ICS/formoterol as AIR for mild exacerbations (alternative to SABA)
• Increase maintenance ICS dose 4-5 fold
• Oral corticosteroids if not responding

• Salbutamol up to 3 times, 20-30 min apart (GINA 2026 specifies dosing)
• Ipratropium 4 puffs with salbutamol for up to 3 times
• Oral/IV corticosteroids initiated
• Supplemental oxygen (GINA 2026 updated SpO₂ targets)
• IV magnesium sulfate 2g over 20 min for life-threatening/refractory cases
• Heliox (helium-oxygen mixture) - reduces work of breathing in very severe cases
• NIV may be considered in selected patients
• ICU + intubation for respiratory failure (mechanical ventilation is challenging - increased risk of barotrauma, air-trapping, permissive hypercapnia strategy)

After Acute Attack:

• Oral corticosteroids typically for 5-7 days
• Increase controller therapy
• Arrange early follow-up (within 1 week)
• GINA 2026: updated discharge planning and follow-up protocols

---

12. Special Considerations

Asthma in Pregnancy

• ~4% of pregnant women have asthma; ~1/3 worsen during pregnancy
• FEV₁ and PEFR unchanged in pregnancy (useful for monitoring)
• Progesterone → increased tidal volume + minute ventilation (normal in pregnancy)
• ABG in pregnancy: pH 7.45, PaCO₂ 27-32 mmHg (respiratory alkalosis = normal)
• A normal PaCO₂ (40 mmHg) in a pregnant asthmatic = hypercapnia relative to normal pregnancy values
• Moderate-severe asthma in pregnancy increases risk of preterm labor, low birth weight, perinatal death, preeclampsia
• ICS are safe in pregnancy - undertreated asthma is far more dangerous to the fetus than ICS

Aspirin-Exacerbated Respiratory Disease (AERD)

• Triad: asthma + nasal polyposis + hypersensitivity to aspirin/NSAIDs
• Mechanism: Cyclooxygenase-1 inhibition → shunting of arachidonic acid toward leukotriene pathway
• Nasal polyps in adults should raise suspicion
• Management: Avoid NSAIDs; LTRAs (zafirlukast/montelukast) helpful; aspirin desensitization

Asthma-COPD Overlap (ACO)

• Features of both asthma (reversibility, AHR, eosinophilia) and COPD (incomplete reversibility, smoking history, emphysema on CT)
• Treatment is complex; ICS important; long-acting bronchodilators
• SABA monotherapy alone is contraindicated

Occupational Asthma

• Sensitizer-induced: develops after a latency period; caused by high MW (proteins) or low MW (chemicals like isocyanates) agents
• Irritant-induced (RADS): after single, high-level irritant exposure; no latency period
• Diagnosis: serial PEF measurements at work and away; specific bronchial challenge; reduction on vacation = diagnostic clue

---

13. Monitoring Parameters

---

14. Fatality Risk Indicators (GINA 2026 - New Focus)

• Previous near-fatal attack (intubation, ICU)
• Hospitalization for asthma in past year
• Currently not using ICS or poor adherence
• Currently using or recently stopped OCS
• Overuse of SABA (>1 canister/month)
• No written asthma action plan
• History of psychiatric illness or psychosocial problems
• Food allergy with confirmed sensitization
• Comorbid cardiovascular disease

---

15. Quick Reference Summary

ASTHMA = Episodic obstruction + AHR + Inflammation (usually eosinophilic)

Diagnosis: Symptoms + reversible obstruction on spirometry 
           OR positive bronchial provocation (PC20 <8 mg/mL)

T2 biomarkers: FeNO ≥40, eosinophils ≥300/µL, elevated IgE

Reliever (ALL steps): ICS/formoterol (AIR) - NOT SABA alone [GINA 2026]

Controller hierarchy:
Step 1-2: Low ICS ± LTRA
Step 3:   ICS/LABA
Step 4:   Medium ICS/LABA ± LAMA
Step 5:   Biologic (anti-IgE, anti-IL-5, anti-IL-4Rα, anti-TSLP)

Acute severe: SABA + ipratropium + OCS; Mg²⁺ for life-threatening
Silent chest + normal PaCO₂ = DANGER signs

Biologics (T2): Omalizumab, mepolizumab, reslizumab, benralizumab,
               dupilumab, tezepelumab, depemokimab (NEW 2026)

---

1. ICS/formoterol as AIR at ALL steps (including Step 1) - reducing OCS need
2. New biologic: Depemokimab for severe eosinophilic asthma (≥12y) and CRSwNP (≥18y)
3. Updated fatality risk indicators - greater emphasis on prevention of asthma death
4. New assessment tools: CAAT, Peds-AIRQ, PRAM
5. Updated SpO₂ targets and SABA dosing in acute management
6. Biologic decision tree updated for T2 inflammation with comorbidity consideration

---

1. Definition & Epidemiology
2. Pathophysiology - Type 2 vs Non-Type 2 inflammation, airway remodeling, AHR mechanisms, with the airway cross-section diagram
3. ICS Pharmacology - oral bioavailability comparison, systemic effects
4. Classification - phenotypes (allergic, eosinophilic, AERD, obesity-associated, neutrophilic, occupational)
5. Triggers - allergens, viral infections, drugs (beta-blockers, aspirin, ACE inhibitors), exercise, pollution
6. Clinical Features - symptoms, physical exam, control assessment table
7. Diagnosis - spirometry, PEFR, bronchial provocation (PC20), FeNO, blood eosinophils, skin testing
8. Comorbidities - rhinosinusitis, GERD, obesity, OSA, vocal cord dysfunction, anxiety
9. Medications - SABAs, LABAs, ICS (agents + bioavailability), LAMAs, LTRAs (montelukast warning), theophylline, all biologics
10. Stepwise Management (GINA 2026) - including the AIR (Anti-Inflammatory Reliever) paradigm shift
11. Acute Severe Asthma - severity grading table, management protocol, danger signs
12. Special Situations - pregnancy, AERD, ACO, occupational asthma
13. GINA 2026 Key Updates - depemokimab, new assessment tools, fatality risk indicators

---

ASTHMA - Deep Dive (Extended PGT Reference)

---

PART 1: EPIDEMIOLOGY (in depth)

• ~262 million people affected globally (Harrison's 2025)
• US prevalence: 7.9% (vs ~4.3% worldwide); has been rising since 2001 (was 7.3%)
• More common in children (8.4%) than adults (7.7%)
• Children: 2:1 male > female ratio
• Adults: female > male (hormonal influence)
• Highest US prevalence: Puerto Rican population; highest morbidity in Black race
• 1.8 million US ED visits/year; 189,000 hospitalizations (2016 data)
• Total US economic cost: $82 billion (2013)
• Asthma mortality: rose in 1960s (due to overuse of high-potency inhaled β₂-agonists); declined after 1990s with widespread ICS use; mortality rate declined from 0.44 per 100,000 (1993) to 0.19 (2006) - but no further reduction since then
• COVID-19 pandemic → nearly 50% reduction in exacerbations (attributed to decreased viral infections from social distancing)

---

PART 2: PATHOGENESIS - FROM ALLERGEN TO AIRWAY (Molecular Detail)

2.1 The Asthma Development Pathway

GENETIC SUSCEPTIBILITY
        +
ENVIRONMENTAL EXPOSURES (allergens, pollution, infections, tobacco)
        +
DEVELOPMENTAL FACTORS (aging, hormonal changes, obesity)
        ↓
Airway Hyperresponsiveness
        +
Airway Inflammation (Type 2 or non-Type 2)
        +
Structural Changes (Remodeling)
        ↓
ASTHMA (symptoms ← triggers → exacerbations)

2.2 The Allergic (IgE-mediated) Cascade

1. Allergen enters airway mucosa
2. Captured by dendritic cells → processed → presented via MHCII to naive T-cells
3. In atopic individuals → Th2 polarization (master transcription factor: GATA-3)
4. Th2 cells produce: IL-4 (drives B-cell class switching to IgE), IL-5 (eosinophil survival/activation), IL-13 (mucus production, AHR, IgE)
5. B-cells produce IgE antibodies → bind to FcεRI receptors on mast cells and basophils

1. Allergen cross-links surface-bound IgE on mast cells
2. Mast cell degranulation → rapid release of preformed mediators (within minutes)
3. New mediator synthesis occurs over hours

2.3 Mast Cell - The Central Effector Cell

Biphasic Response: The initial bronchoconstriction (early asthmatic response, EAR) reflects histamine, PG, and leukotriene effects. The late-phase reaction (LAR, 4-6h later) is cytokine/eosinophil-mediated sustained inflammation. Corticosteroids suppress the late phase but NOT the early phase. LTRAs suppress BOTH phases.

2.4 The Alarmin Cascade (Innate Immunity - Critical for PGT)

ILC2s (Innate Lymphoid Cells type 2) can drive T2 inflammation without allergen sensitization - this explains non-allergic eosinophilic asthma. TSLP is the most upstream alarmin and the broadest therapeutic target (tezepelumab).

2.5 Eosinophil in Asthma

• IL-5 (differentiation from bone marrow progenitors)
• Eotaxins (CCL11, CCL24, CCL26) via CCR3 receptor on eosinophils
• VCAM-1 on endothelium (upregulated by IL-4)

2.6 Type 2 vs Non-Type 2 Detailed Comparison

2.7 Airway Remodeling (Structural Changes)

Remodeling begins early - subepithelial fibrosis is found even at disease onset. Corticosteroids suppress inflammation but do NOT consistently reverse remodeling. This is why prevention of progression is critical.

---

PART 3: GENETICS & RISK FACTORS

Genetic Factors

• Asthma has strong genetic heritability (~60-80% in twins)
• Candidate genes cluster around:
  • Chromosome 5q31-33: IL-4, IL-5, IL-13, IL-9, GM-CSF gene cluster; β₂-adrenergic receptor
  • Chromosome 11q13: FcεRI β-chain (high-affinity IgE receptor)
  • Chromosome 12q: IFN-γ, stem cell factor, IGF
  • Chromosome 13q: BRCA2, IgE regulation
  • ORMDL3/GSDMB (chromosome 17q21): one of the strongest GWAS associations for childhood asthma
• β₂-receptor polymorphism at amino acid 16 (Arg→Gly): Gly/Gly homozygotes show greater tachyphylaxis with regular SABA use and increased AHR

Risk Factors for Development

---

PART 4: DIAGNOSIS IN DETAIL

4.1 Pulmonary Function Testing

• FEV₁ may be normal or near-normal in mild asthma - does NOT exclude the diagnosis
• Diagnosis may be difficult to confirm after starting ICS (obstruction and AHR mitigate with therapy) - if diagnosis uncertain, trial of medication taper may be needed
• Low FEV₁ = strongest objective predictor of poor asthma control and need for acute care

4.2 Bronchial Provocation Testing

• Direct smooth muscle stimulation via M₃ muscarinic receptors
• PC₂₀ <8 mg/mL = significant AHR (positive test)
• False positives: COPD, allergic rhinitis, heart failure, recent viral URTI (persists 4-6 weeks)
• If FEV₁ normal → use PC₂₅ for impairment rating

• Hyperventilation → airway desiccation → osmolarity change in lining fluid → mediator release
• >10-15% fall in FEV₁ post-exercise = positive
• More specific for exercise-induced bronchoconstriction

• Osmotic challenge - desiccates airway surface → mediator release
• Positive: ≥15% fall in FEV₁ at cumulative dose ≤635 mg
• Better specificity than methacholine for confirming active asthma

4.3 FeNO Interpretation

• FeNO is driven primarily by IL-13 → inducible NO synthase in airway epithelium
• Elevated in eosinophilic asthma, AERD, allergic rhinitis
• Falls with ICS - useful for monitoring adherence and adjusting dose
• NOT affected by acute bronchodilators
• Smoking falsely LOWERS FeNO
• Tall height and atopy increase FeNO

4.4 Sputum Eosinophil Count

• Eosinophils >2-3% = eosinophilic asthma; predicts ICS response and exacerbation risk
• Gold standard for T2 phenotyping but invasive; mainly used in research/specialist centres
• Useful to guide ICS dose titration in severe asthma (reduces exacerbations better than symptom-guided titration)

4.5 Blood Eosinophil Count (BEC)

4.6 Differential Diagnosis

---

PART 5: PHARMACOLOGY - MOLECULAR MECHANISMS

5.1 β₂-Agonist Mechanism (Molecular Detail)

β₂ receptor → Gs protein → Adenylyl cyclase 
→ ↑cAMP → Protein Kinase A (PKA) activation
→ Phosphorylation of:
   • Myosin light chain kinase (MLCK) → inhibited → smooth muscle RELAXATION
   • K+ channels (Ca²⁺-activated K+) → opens → hyperpolarization → relaxation
   • Decreased PI hydrolysis (↓IP₃ → ↓intracellular Ca²⁺)
   • Increased Na⁺/K⁺-ATPase activity
   • Increased myosin light chain phosphatase activity

• Inhibit mast cell mediator release (via β₂ on mast cells)
• Prevent microvascular leakage (reduce edema from histamine/LTD₄/PGD₂)
• Increase mucociliary clearance (enhance ion transport + mucus secretion from submucosal glands)
• Inhibit ACh release from presynaptic β₂ receptors on cholinergic nerves

• β₂-agonists are functional antagonists (relieve symptoms) but have NO anti-inflammatory effect
• Regular SABA use → tachyphylaxis of bronchoprotective effect
• Arg16 polymorphism patients: regular SABA → increased airway reactivity
• Increased SABA use = marker of poor control = associated with increased asthma mortality
• Hence GINA 2026 mandates ICS/formoterol as AIR (not SABA alone)

• Formoterol: moderate lipophilicity → stays near membrane receptor → slow-release property → but in plasma, loses this → can act rapidly; onset comparable to SABA (3-5 min)
• Salmeterol: long aliphatic chain anchored in receptor "exosite" → cannot dissociate rapidly → slow onset → NOT suitable as reliever

5.2 ICS Mechanism (Molecular Detail)

ICS molecule → enters cell → binds cytoplasmic glucocorticoid receptor (GR)
→ GR-ICS complex translocates to nucleus
→ Two mechanisms:

1. Trans-repression (anti-inflammatory - main effect):
   Binds to NF-κB and AP-1 transcription factors
   → Inhibits expression of inflammatory genes:
     (IL-4, IL-5, IL-13, TNF-α, ICAM-1, Cox-2, iNOS)
   → Reduces FeNO, eosinophil counts, AHR

2. Trans-activation (side effects - via GRE binding):
   Upregulates anti-inflammatory proteins (annexin-1, SLPI)
   → Also responsible for: growth suppression, bone loss, cataracts, skin thinning

5.3 ICS Resistance

• Reduced GR expression in inflammatory cells
• GR-β isoform (acts as dominant negative inhibitor of GR-α)
• NF-κB/AP-1 overactivation (overcomes steroid suppression)
• HDAC2 (histone deacetylase 2) reduction - required for ICS to work; reduced by oxidative stress (smoking, severe asthma)
• Macrophage-predominant neutrophilic inflammation - inherently ICS-resistant

5.4 Anticholinergic Mechanism

Cholinergic nerve stimulation → ACh release → M₃ receptor on smooth muscle
→ ↑IP₃ → ↑Ca²⁺ → smooth muscle CONTRACTION

Anticholinergics (SAMA/LAMA) → M₃ receptor blockade → smooth muscle RELAXATION

• Less effective than β₂-agonists as bronchodilators (ACh is only one bronchoconstrictor pathway)
• Also block M₃ receptors on submucosal glands → reduce mucus secretion
• M₂ receptors (presynaptic, autoinhibitory) - if blocked → increased ACh release (pro-constrictive)
• Tiotropium (LAMA): preferential M₃/M₁ kinetics → functional selectivity despite non-selective binding

5.5 Leukotriene Pathway and LTRAs

Arachidonic acid → 5-lipoxygenase (5-LO) + 5-LO activating protein (FLAP)
→ LTA₄ → LTC₄ (via glutathione-S-transferase)
→ secreted → cleaved to LTD₄ → LTE₄

All bind CysLT₁ receptor on smooth muscle, mucus glands, inflammatory cells
→ Bronchoconstriction + mucus hypersecretion + eosinophil recruitment + vascular permeability

LTRA (montelukast, zafirlukast) → CysLT₁ receptor antagonism
→ Reduces: early AND late phase response, exercise-induced bronchoconstriction,
   aspirin-triggered bronchoconstriction (AERD), nasal polyp growth

Leukotrienes are 1000x more potent than histamine as bronchoconstrictors. LTD₄ = most potent. FDA black box warning on montelukast (2020): serious neuropsychiatric events including suicidal ideation, depression, nightmares, aggression - must inform patients before prescribing.

---

PART 6: BIOLOGICS - FULL MECHANISTIC GUIDE

6.1 Overview - How Biologics Target T2 Inflammation

Allergen/Damage
     ↓
EPITHELIUM → TSLP → [Tezepelumab]
             IL-33 → [Itepekimab (in trials)]
             IL-25
     ↓
ILC2 / Th2
     ↓
IL-4  → IgE class switch → IgE → [Omalizumab / Omalizumab-igec]
IL-5  → Eosinophil maturation/survival → [Mepolizumab, Reslizumab]
                              ↓ IL-5Rα → [Benralizumab, Depemokimab]
IL-13 → Mucus, AHR, fibrosis
 ↕
IL-4Rα (shared receptor subunit for IL-4 and IL-13) → [Dupilumab]

6.2 Individual Biologics

Step 5 Severe Asthma - Need Biologic?
        ↓
Check T2 biomarkers (blood eos, FeNO, IgE, allergen sensitization)
        ↓
If ALLERGIC + elevated IgE → Omalizumab (or omalizumab-igec)
If EOSINOPHILIC (eos ≥300) → Anti-IL-5: Mepolizumab / Benralizumab / Reslizumab / Depemokimab
If EOSINOPHILIC + ATOPIC DERMATITIS/CRSwNP → Dupilumab (addresses "one airway" disease)
If BROAD T2 or UNCERTAIN or T2-LOW with eos → Tezepelumab (upstream, broadest)
If ALL T2 POSITIVE → Choose based on comorbidities, cost, route, frequency, patient preference

---

PART 7: GINA 2026 STEPWISE MANAGEMENT - FULL TABLE

• Step UP: If poorly controlled for ≥2-3 months; FIRST check: adherence, inhaler technique, trigger avoidance, comorbidities
• Step DOWN: When well-controlled for ≥3 months; do NOT fully stop ICS (risk of rebound)
• Never stop ICS suddenly in any patient at any step

---

PART 8: STATUS ASTHMATICUS - DEEP ICU MANAGEMENT

8.1 Definition

8.2 Pathophysiology of Acute Attack

Bronchoconstriction + airway edema + mucus plugging
↓
Air trapping → dynamic hyperinflation
↓
↑ Intrinsic PEEP (auto-PEEP) → increased work of breathing
↓
Respiratory muscle fatigue → Hypercapnia (DANGER)
↓
Respiratory failure → Cardiorespiratory arrest

Key exam point: A "normal" PaCO₂ in an acutely distressed asthmatic indicates impending respiratory failure. Most asthmatics should be hypocapnic during an attack.

8.3 Emergency Management Protocol

1. Supplemental O₂ to maintain SpO₂ 93-95% (GINA 2026 specifies updated SpO₂ targets; avoid hyperoxia)
2. Salbutamol (albuterol) via MDI+spacer (4-8 puffs) OR nebuliser - repeat every 20 min up to 3 times
3. Ipratropium bromide 4-8 puffs via MDI OR 0.5 mg nebulised - with each salbutamol dose (up to 3 times)
4. Systemic corticosteroids: Oral prednisolone 40-50 mg OR IV hydrocortisone 100-200 mg if cannot swallow; onset of effect 4-6h

• Indications: Impending/actual respiratory failure, deteriorating mental status, PaCO₂ rising + acidosis, silent chest, exhaustion
• Challenges: High airway resistance → high peak pressures → risk of barotrauma, pneumothorax
• Mechanical ventilation strategy:
  • Low respiratory rate (RR 8-12/min) + low tidal volume (6-8 mL/kg IBW)
  • Long expiratory time (I:E ratio 1:3 or 1:4) to minimize auto-PEEP and air trapping
  • Permissive hypercapnia: Allow PaCO₂ to rise (accept pH ≥7.2); correct severe acidosis with sodium bicarbonate if pH <7.2
  • Neuromuscular paralysis (short-term) to reduce peak airway pressures
  • Ketamine as induction agent: bronchodilator properties via catecholamine release; drug of choice for intubation in severe asthma
  • Volatile anaesthetic agents (isoflurane, sevoflurane): potent bronchodilators; use in refractory cases at specialist centres; associated with increased ventilator length in some studies
  • Bronchoscopy to clear mucus plugs: described but potentially dangerous during difficult MV; reserved for selected cases

8.4 Asthma Mortality Risk Factors (Harrison's 2025)

1. History of ICU admission for asthma
2. History of intubation for asthma
3. Illicit drug use
4. Depression
5. New diagnosis within past year
6. ≥2 ED visits in past 6 months
7. Severe psychosocial problems
8. Lower socioeconomic status
9. ≥2 courses of systemic corticosteroids in past year
10. Overuse of SABAs (>1 canister/month)
11. Currently not on ICS or non-adherent

---

PART 9: SPECIAL SCENARIOS (Detailed)

9.1 Exercise-Induced Bronchoconstriction (EIB)

• Exercise → hyperventilation → desiccation of airway lining fluid → osmolarity change in airway surface liquid → mast cell degranulation → mediator release (LTs, PGs, histamine) → bronchoconstriction
• Cold air compounds this (lower absolute moisture; rewarming also causes edema)
• EIB usually peaks 5-15 minutes after exercise and resolves 30-60 min spontaneously

• 10-15% fall in FEV₁ within 15-30 min of standardized exercise challenge

• Distinguish from refractory period (2h window after exercise where subsequent exercise causes less bronchoconstriction - related to mast cell mediator depletion)

• ICS (long-term anti-inflammatory - reduces mast cell activity)
• Pre-treatment: SABA 15-20 min before exercise; or ICS/formoterol (single dose)
• LABAs for occasional exercise: can extend bronchoprotection but NOT recommended for monotherapy
• Warm-up exercises before vigorous activity (exploits refractory period)
• Breathing through nose/warm scarf in cold weather

9.2 Aspirin-Exacerbated Respiratory Disease (AERD)

Aspirin/NSAID → COX-1 inhibition
↓
Arachidonic acid NOT converted to PGs (especially PGE₂ - bronchodilatory)
↓
Shunting → 5-LO pathway → overproduction of CysLTs
↓
Massive bronchoconstriction + rhinorrhoea + urticaria

• Avoid COX-1 inhibitors (aspirin, ibuprofen, naproxen, diclofenac, indomethacin)
• Safe alternatives: Paracetamol (acetaminophen) at low doses; COX-2 selective inhibitors (celecoxib - use cautiously)
• LTRAs (montelukast, zafirlukast) - reduce severity
• Aspirin desensitization: Gradual incremental aspirin doses in supervised setting → tolerance; allows aspirin for cardiovascular disease; reduces polyp recurrence and systemic steroid need
• Dupilumab and tezepelumab show efficacy for AERD-associated nasal polyps

9.3 Asthma-COPD Overlap (ACO)

• ICS are mandatory (reduces mortality in ACO vs ICS withdrawal)
• LABA/LAMA as add-on
• SABA as reliever
• SABA monotherapy is contraindicated in ACO
• Pulmonary rehabilitation for functional limitation
• Manage comorbidities (cardiovascular disease, osteoporosis from long-term OCS)

---

PART 10: MONITORING FRAMEWORK (GINA 2026)

10.1 Asthma Control Questionnaires

• 5 questions covering past 4 weeks; scored 5-25
• ≤19 = poorly controlled; ≥20 = well controlled; 25 = fully controlled

• 6-7 items; score 0-6; higher = worse control
• Score >1.5 = uncontrolled; <0.75 = controlled

• CAAT (Chronic Airways Assessment Test) - for patients with both asthma and COPD features
• Peds-AIRQ (Pediatric Asthma Impairment and Risk Questionnaire)
• PRAM (Pediatric Respiratory Assessment Measure) - for acute exacerbation severity in children

10.2 Written Asthma Action Plan

• Every patient should have a written action plan
• Based on symptoms or PEFR (green/yellow/red zones)
• Specifies: when to increase reliever, when to start OCS, when to go to ED
• Absence of written plan = fatality risk factor

---

PART 11: ASTHMA vs COPD at a Glance

---

• Harrison's Principles of Internal Medicine 22E (2025), Chapter 298 (Asthma)
• Goodman & Gilman's Pharmacological Basis of Therapeutics, Chapter 44 (Pulmonary Pharmacology)
• Cellular and Molecular Immunology (Abbas), Chapter 20 (Immediate Hypersensitivity)
• Murray & Nadel's Textbook of Respiratory Medicine, Chapters 62, 27 (Asthma Assessment, Sleep)
• Fishman's Pulmonary Diseases and Disorders, Chapter on Asthma
• GINA 2026 Global Strategy Report (released May 5, 2026)
• Systematic Review, PMID 40520782: Umbrella review of biologics for severe asthma (2025)

---

What's inside (6 pages, colour-coded)

---

COPD - Comprehensive Final Exam Guide

Based on GOLD 2026 | Harrison's 22E | Fishman's Pulmonary | Robbins Pathology | Katzung Pharmacology

---

1. DEFINITION

---

2. EPIDEMIOLOGY

---

3. ETIOLOGY & RISK FACTORS

Major Risk Factors

• Cigarette smoking (by far the most important): dose-dependent; pack-years correlate with severity
• Biomass fuel exposure (cooking smoke - major cause in low-income countries, especially women)
• Occupational exposures: coal dust, silica, grain dust, cadmium
• Air pollution (indoor + outdoor)
• Recurrent respiratory infections in childhood
• Low birth weight / impaired lung development
• Alpha-1 antitrypsin (A1AT) deficiency - genetic cause

Alpha-1 Antitrypsin Deficiency (Important Exam Topic)

• Autosomal co-dominant inheritance
• PiZZ phenotype = severe deficiency; PiMZ = intermediate
• A1AT is a serine protease inhibitor that neutralises neutrophil elastase
• Deficiency → unopposed elastase activity → panacinar emphysema (lower lobe predominant)
• Also causes liver cirrhosis (misfolded protein accumulates in hepatocytes)
• ATS recommends testing all patients with persistent airflow obstruction for A1AT levels
• Treatment: intravenous A1AT augmentation therapy (weekly IV infusions)

---

4. PATHOLOGY

4a. Emphysema Types

4b. Chronic Bronchitis Pathology

• Clinical definition: Productive cough for ≥3 months in ≥2 consecutive years (no other cause)
• Pathological changes:
  • Reid index >0.4 (gland thickness / bronchial wall thickness; normal <0.4)
  • Hyperplasia of submucosal mucous glands (Reid index)
  • Goblet cell metaplasia in small airways
  • Inflammatory infiltrate (predominantly neutrophilic)
  • Bronchiolar wall fibrosis
  • Ciliary dysfunction → impaired mucociliary clearance
• MUC5AC concentration increased 10-fold, MUC5B 3-fold in severe COPD (Fishman's)

---

5. PATHOPHYSIOLOGY

5a. Protease-Antiprotease Imbalance

• Trigger: Cigarette smoke / noxious particles → oxidative stress → recruit neutrophils and macrophages
• Neutrophils release elastase (matrix metalloproteinases + serine proteases)
• A1AT (produced by liver) normally inhibits neutrophil elastase
• Oxidative stress from cigarette smoke inactivates A1AT
• Net result: Unopposed elastase destroys elastin and type IV collagen in alveolar walls → enlarged airspaces → emphysema
• Loss of elastic recoil → airway collapse on expiration → airflow obstruction

5b. Inflammation Profile

• Dominant cell: Neutrophil (unlike asthma which is eosinophilic)
• Also: CD8+ T-cells, macrophages, mast cells in some patients
• Inflammatory mediators: IL-8, TNF-α, LTB₄, MMP-9, MMP-12
• ICS are poorly effective because neutrophilic inflammation is corticosteroid-resistant

5c. Small Airway Disease

• Earliest change: Inflammation and fibrosis of small airways (<2mm diameter)
• Small airways account for only 25% of total airway resistance normally, but become major site of obstruction in COPD
• Small airway obstruction precedes detectable spirometric changes
• CT can detect small airway mucus plugging even with preserved FEV₁

5d. Dynamic Hyperinflation (Important Exam Mechanism)

• Loss of elastic recoil → static hyperinflation (increased FRC at rest)
• During exercise: increased ventilatory demand + insufficient expiratory time → air trapping → dynamic hyperinflation
• End-expiratory lung volume (EELV) rises → inspiratory reserve volume (IRV) falls critically
• Creates neuromechanical uncoupling (effort disproportionate to VT response) → sensation of dyspnoea
• Barrel chest = compensatory increase in AP diameter due to chronically elevated FRC
• Flattened diaphragm on CXR/CT due to hyperinflation

5e. Gas Exchange Abnormalities

• V/Q mismatch is the primary mechanism of hypoxaemia in COPD
• Perfused but poorly ventilated alveoli (low V/Q) → venous admixture → ↓PaO₂
• Unlike asthma, A-a gradient is elevated (measured PaO₂ << calculated PAO₂)
• Alveolar gas equation: PAO₂ = PiO₂ - PaCO₂/R = 150 - PaCO₂/0.8
• Early COPD: Hypoxaemia + hypocapnia (hyperventilation compensates)
• Late COPD (type B "blue bloater"): Hypoxaemia + hypercapnia + respiratory acidosis
• Emphysema patients tend to maintain normocarbia longer ("pink puffer")

5f. Pink Puffer vs Blue Bloater (Classic Teaching)

---

6. CLINICAL FEATURES

Symptoms (Classic Triad)

1. Dyspnoea - progressive, worse on exertion; described as "breathlessness" or "air hunger"; MRC scale used
2. Chronic cough - may be intermittent; productive or dry
3. Sputum production - chronic bronchitis phenotype; purulent during exacerbations

Signs

---

7. INVESTIGATIONS

Spirometry (Mandatory for Diagnosis)

Chest X-Ray (CXR) Findings

• Hyperinflation: >6 anterior ribs visible; flat hemidiaphragms (below rib 6 anteriorly)
• Increased AP diameter on lateral view
• Hyperlucent lung fields (reduced vascular markings)
• Bullae formation
• Increased retrosternal airspace on lateral CXR

HRCT Thorax

• Low-attenuation areas = emphysema (quantified as % of lung below -950 HU threshold)
• Air trapping on expiratory CT
• Small airway mucus plugging
• Airway wall thickening (chronic bronchitis)
• Bronchiectasis (15-30% of COPD patients have concomitant bronchiectasis)

Blood Tests

• FBC: Polycythaemia (chronic hypoxia → ↑EPO → ↑RBC)
• ABG: Hypoxaemia ± hypercapnia; pH; HCO₃⁻ (chronic compensation)
• A1AT level: Test all patients with airflow obstruction (ATS recommendation)
• Blood eosinophil count (BEC): Critical biomarker for treatment decisions (ICS, dupilumab)
• BNP/NT-proBNP: Elevated in cor pulmonale / right heart failure

ECG

• P pulmonale (peaked P waves >2.5mm in II, III, aVF)
• Right axis deviation
• Right ventricular hypertrophy pattern
• Low voltage (hyperinflation)

---

8. GOLD ABE CLASSIFICATION (GOLD 2026 Update)

Assessment Dimensions

1. Spirometry (GOLD grade 1-4) - for severity of airflow obstruction
2. Symptoms - assessed with mMRC ≥2 or CAT ≥10
3. Exacerbation history - key determinant of treatment

Groups A, B, E

---

9. PHARMACOLOGICAL MANAGEMENT

9a. Bronchodilators (Mainstay)

• Tiotropium (Spiriva), umeclidinium, glycopyrronium, aclidinium
• Mechanism: M₃ receptor blockade → ↓ACh-mediated bronchoconstriction; also reduce mucus secretion
• Once daily (tiotropium, umeclidinium) or twice daily
• Preferred initial bronchodilator in COPD (outperform LABAs on lung function + exacerbations in most head-to-head trials)

• Salmeterol, formoterol, indacaterol, olodaterol, vilanterol
• Duration 12h (salmeterol, formoterol) or 24h (indacaterol, vilanterol, olodaterol)

• Preferred for Group B and most Group E patients
• Greater bronchodilation + exacerbation reduction vs. monotherapy
• Examples: umeclidinium/vilanterol (Anoro), tiotropium/olodaterol (Spiolto), glycopyrronium/indacaterol (Ultibro)

• Salbutamol (SABA), ipratropium (SAMA)
• For rescue/PRN use
• Combined SABA+SAMA (combivent) for acute use

9b. Inhaled Corticosteroids (ICS) - Conditional Use

• Persistent exacerbations despite LABA+LAMA
• BEC ≥300 cells/µL
• Concurrent asthma-COPD overlap (ACO) - ICS mandatory

• Pneumonia (most important - relative risk ↑ with FP vs budesonide)
• Oral candidiasis
• HPA axis suppression
• Osteoporosis

9c. Triple Therapy (LABA + LAMA + ICS)

• For Group E patients with persistent exacerbations despite LABA+LAMA
• Particularly when BEC ≥100 (more benefit with higher eosinophils)
• GOLD 2026: Triple therapy threshold lowered; more prominently integrated
• Evidence: IMPACT, ETHOS, TRINITY, TRIBUTE trials - all show class effect in reducing exacerbations and improving FEV₁

• Budesonide/formoterol/glycopyrronium (Breztri Aerosphere)
• Fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta)

9d. Roflumilast (PDE4 Inhibitor)

• Selective phosphodiesterase-4 inhibitor → ↑cAMP → anti-inflammatory
• Indication: GOLD 3-4 + chronic bronchitis phenotype + frequent exacerbations despite maximal ICS/LABA/LAMA
• Reduces exacerbations by ~15-17%
• Side effects: Nausea, diarrhoea, weight loss, psychiatric effects - limit use
• Note: Not a bronchodilator - purely anti-inflammatory

9e. Azithromycin (Long-term antibiotic)

• 250mg/day or 500mg 3×/week
• Reduces exacerbation frequency by ~27% in selected patients
• Mechanism: Anti-inflammatory + anti-bacterial (against H. influenzae, non-typeable H. influenzae)
• Concerns: Hearing loss, cardiac arrhythmias (QTc prolongation), antibiotic resistance
• Indication: Former/non-smokers, frequent exacerbators, elderly

9f. Mucolytics

• N-acetylcysteine (NAC), carbocisteine, erdosteine
• Reduce viscosity of mucus; some antioxidant effect
• Recent systematic review (PMID: 39413571, 2024): modest benefit on exacerbation reduction in stable COPD
• Indicated especially in chronic bronchitis phenotype

9g. Biologics (GOLD 2026 - New Integration)

• BOREAS and NOTUS trials
• Indication: COPD + chronic bronchitis phenotype + BEC ≥300 cells/µL + uncontrolled on triple therapy
• Reduces moderate-severe exacerbations by 30-34% + improves FEV₁
• Only biologic currently with strong evidence base for COPD
• GOLD 2026 positions this as an additional option after triple therapy failure in eosinophilic COPD

• PMID: 40626315 (2025 network meta-analysis) supports type-2 biologics in COPD
• Evidence emerging but not yet as strong as dupilumab

---

10. NON-PHARMACOLOGICAL MANAGEMENT

Smoking Cessation

• Single most effective intervention to slow FEV₁ decline
• Fletcher-Peto curves: accelerated FEV₁ decline in susceptible smokers; stops with cessation
• Methods: Nicotine replacement therapy (NRT), varenicline (preferred: 2× more effective), bupropion, behavioural support
• Even after decades of smoking - cessation slows progression

Pulmonary Rehabilitation (PR)

• Strongest evidence for improving dyspnoea, exercise capacity, and QoL
• Does NOT improve FEV₁ or mortality significantly in isolation
• Components: Aerobic exercise, strength training, education, nutritional support, psychosocial support
• Duration: 6-8 weeks (minimum); 12 weeks preferred
• Must be initiated within 4 weeks after exacerbation (post-exacerbation PR reduces readmissions)

Long-Term Oxygen Therapy (LTOT)

• PaO₂ ≤55 mmHg (7.3 kPa) at rest on room air
• PaO₂ 56-59 mmHg (7.3-8.0 kPa) PLUS one of: cor pulmonale, polycythaemia (Hct >55%), pulmonary hypertension

Vaccination (GOLD 2026 - Core Disease-Modifying Strategy)

Lung Volume Reduction Surgery (LVRS)

• Removes most diseased portions of lung (typically upper lobes)
• Improves elastic recoil, reduces hyperinflation, improves diaphragm mechanics
• Best candidates: Upper-lobe predominant emphysema + low exercise capacity after PR
• NETT trial: Mortality benefit in upper-lobe COPD with low post-PR exercise

Bronchoscopic Lung Volume Reduction (BLVR)

• Endobronchial valves (Zephyr, Spiration): one-way valves → lobar atelectasis → reduce hyperinflation
• Coils, thermal vapour ablation - alternative modalities
• Requires absence of collateral ventilation (Chartis assessment or fissure completeness on CT)

Lung Transplantation

• End-stage COPD (GOLD 4) failing maximal therapy
• Single or bilateral lung transplant
• BODE index used for listing prioritisation (BMI, Obstruction, Dyspnoea, Exercise)

---

11. EXACERBATIONS OF COPD (AECOPD)

Definition

Triggers

• Viral infections: 50-80% (rhinovirus, influenza, parainfluenza, RSV, coronavirus)
• Bacterial infections: 40-60% H. influenzae (most common), Streptococcus pneumoniae, Moraxella catarrhalis, Pseudomonas (severe COPD)
• Air pollution
• Pulmonary embolism (frequently overlooked - check D-dimer/CTPA)

Severity Classification (GOLD 2026 Revised)

Management of Acute Exacerbation

• Increase dose/frequency of SABAs (salbutamol 2.5-5mg neb q20min)
• Add ipratropium 0.5mg neb
• Continue LABAs and LAMAs

• Prednisolone 30-40mg/day for 5 days (REDUCE trial: 5 days = 14 days; no benefit to longer)
• Reduces exacerbation duration and hospital stay

• Indicated if: purulent sputum AND increased dyspnoea AND increased sputum volume (Anthonisen criteria - 2 or 3 = antibiotics)
• Or if mechanically ventilated
• Choice: Amoxicillin/clavulanate, doxycycline, or azithromycin
• Pseudomonas coverage if: severe COPD (FEV₁ <30%), hospitalised, prior Pseudomonas infection, immunocompromised → ciprofloxacin or anti-pseudomonal beta-lactam

• Target SpO₂ 88-92% (controlled oxygen; avoid hyperoxia)
• High-flow O₂ → ↑ PaCO₂ (Haldane effect + absorption atelectasis + ↓hypoxic drive) → hypercapnic respiratory failure

• Indication: pH <7.35 + PaCO₂ >45 mmHg (type 2 respiratory failure)
• Reduces need for intubation by ~58%, reduces mortality ~48%
• IPAP 12-20 cmH₂O, EPAP 4-8 cmH₂O, FiO₂ titrated
• Contraindications: Vomiting, unable to protect airway, facial trauma, haemodynamic instability

• GOLD 2026 now includes HFNC as a modality in exacerbation management
• Better tolerated than NIV; useful in milder type 2 failure or NIV intolerance

• Failure of NIV, pH <7.25, haemodynamic instability
• Strategy: Low RR + longer expiratory time (I:E 1:3) to avoid auto-PEEP; permissive hypercapnia

---

12. COMPLICATIONS

---

13. PROGNOSTIC INDICES

BODE Index (Best validated prognostic tool)

Other Predictors

• Exacerbation frequency (each exacerbation accelerates FEV₁ decline)
• 6-minute walk distance (6MWT) - most prognostically powerful single test
• FEV₁ decline rate (>50 mL/year = accelerated)
• CT emphysema quantification

---

14. ASTHMA-COPD OVERLAP (ACO)

• Features of both asthma and COPD: variable obstruction + incomplete reversibility
• Spirometry: Post-BD FEV₁/FVC <0.70 + some reversibility (FEV₁ ↑ ≥12% AND ≥200 mL)
• Often: atopic history, blood eosinophilia, elevated FeNO, smoking history
• Critical rule: ICS is MANDATORY in ACO (unlike pure COPD where it is conditional)
• LABA + LAMA can both be used
• ⚠ LABA monotherapy (without ICS) is contraindicated in ACO

---

15. KEY HIGH-YIELD EXAM POINTS

---